PMID- 26680950
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151219
LR  - 20151218
IS  - 1598-2998 (Print)
IS  - 1598-2998 (Linking)
VI  - 35
IP  - 4
DP  - 2003 Aug
TI  - Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in 
      Non-Small Cell Lung Cancer.
PG  - 294-8
LID - 10.4143/crt.2003.35.4.294 [doi]
AB  - PURPOSE: With the increased use of chemotherapy for non small cell lung cancer 
      (NSCLC), a growing group of patients can now be considered for second-line 
      chemotherapy. However, guidelines for the second line treatment remain to be 
      developed. The objective of this study was to evaluate the efficacy and safety of 
      the gemcitabine and vinorelbine combination therapy in patients with advanced 
      NSCLC, pretreated with taxane and platinum based regimens. Gemcitabine has 
      already demonstrated activity in this patient group, with the combination therapy 
      having been reported to be well tolerated in previous phase I/II studies. 
      MATERIALS AND METHODS: Forty two patients with advanced NSCLC (stages III/IV), 
      having received prior taxane and platinum based chemotherapy, with an ECOG 
      performance status (PS) 0~2, and unimpaired hematopoietic and organ function, 
      were treated with vinorelbine, 20 mg/m2, followed by gemcitabine, 1, 000 mg/m2, 
      both administered on days 1, 8 and 15, every 4 weeks. RESULTS: Out of the 42 
      patients enrolled, 41 were evaluable for their response, and all 42 for their 
      toxicity. The patient's characteristics were as follows; median age=60 years 
      (42~73), median PS=1 (range 0~2), a gender ratio 31: 11 males/females, with 
      stages IIIA, IIIB and IV in 3, 14 and 25 cases. The objective responses included 
      a partial response (PR) 8/41 (19.5%), a stable disease 15/41 (36.6%) and a 
      progressive disease 18/41 (43.9%). The median time-to progression (TTP) and 
      survival were 4 months, ranging from 2 to 14 months, and 8 months, ranging from 2 
      to 17+ months, respectively. Grade 3 neutropenia was seen in 19% of the patient, 
      and there was no grade 4 neutropenia or episodes of febrile neutropenia. No grade 
      4 thrombocytopenia or other grade 3/4 non-hematological toxicities were observed. 
      CONCLUSION: The combination of gemcitabine/vinorelbine is active and well 
      tolerated in patients with advanced NSCLC having failed prior taxane/platinum 
      therapy.
FAU - Kim, Yoon Jae
AU  - Kim YJ
FAU - Sohn, Joo Hyuk
AU  - Sohn JH
FAU - Kim, Chul
AU  - Kim C
FAU - Kim, Yong Tai
AU  - Kim YT
FAU - Kim, Hai Jin
AU  - Kim HJ
FAU - Ahn, Joong Bae
AU  - Ahn JB
FAU - Kim, Se Kyu
AU  - Kim SK
FAU - Chang, Joon
AU  - Chang J
FAU - Yoo, Nae Choon
AU  - Yoo NC
FAU - Kim, Joo Hang
AU  - Kim JH
FAU - Cho, Jae Yong
AU  - Cho JY
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
OTO - NOTNLM
OT  - Gemcitabine
OT  - Non-small cell lung cancer
OT  - Second line chemotherapy
OT  - Vinorelbine
EDAT- 2003/08/01 00:00
MHDA- 2003/08/01 00:01
CRDT- 2015/12/19 06:00
PHST- 2015/12/19 06:00 [entrez]
PHST- 2003/08/01 00:00 [pubmed]
PHST- 2003/08/01 00:01 [medline]
AID - 10.4143/crt.2003.35.4.294 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2003 Aug;35(4):294-8. doi: 10.4143/crt.2003.35.4.294.